This was the stock's fourth consecutive day of losses.

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

This was the stock's third consecutive day of losses.

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...